Back to Online Symposia Home Page
|
|
Program Description
A need for education in the long-term management of patients with adolescent and adult ADHD continues to be necessary to provide the much needed patient outcomes.
Learning Objectives
By participating in this activity, you will be able to:
- Describe three measures to accurately identify and diagnose adolescent and adult ADHD
- Identify three consequences of decreased occupational and social functioning, and the impact of decreased quality of life in patients with ADHD
- Evaluate the efficacy and safety of nonpharmacologic and pharmacologic therapeutic options for the treatment of patients with ADHD
Who Will Benefit
This activity was designed to meet the continuing education needs of psychiatrists and other physicians, physician assistants, registered nurses, psychiatric nurses and advanced practice nurses. Other mental health professionals may find this activity informative and should check with their state licensing and certification boards to determine if it meets their continuing education requirements.
Your Distinguished Faculty
Understanding the Challenges in the Diagnosis of Early and Late Adolescent and Adult ADHD
Scott H. Kollins, PhD
Assistant Professor of Psychiatry at Duke Medical Center
Faculty Disclosures
Scott H. Kollins, PhD, has received grants or research support from Athenagen/Comentis, EPA, Eli Lilly and Company, NIDA, NIEHS, NIMH, NINDS, New River, Psychogenics, and Shire. He has also served as a consultant and received honoraria from Athenagen/Comentis, Eli Lilly and Company, NIDA and Shire.
Evaluating Treatment Strategies in the Management of Early and Late Adolescent and Adult ADHD
David W. Goodman, MD
Assistant Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University
Faculty Disclosures
David W. Goodman, MD, is a member of the Speakers Bureau for and has received honoraria from GlaxoSmithKline, Forest Laboratories, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Abbott, Shire Pharmaceuticals Inc., McNeil-PPC, Inc., Wyeth Pharmaceuticals, and Novartis Pharmaceuticals Corporation. He is also a member of the Speakers Bureau for Parke-Davis. Dr. Goodman has received grants and research support from GlaxoSmithKline, Forest Laboratories, Inc., Shire Pharmaceuticals Inc., McNeil-PPC, Inc., Cephalon Inc., and New River Pharmaceuticals. He also serves as a consultant for GlaxoSmithKline, Forest Laboratories, Inc., Eli Lilly and Company, Shire Pharmaceuticals Inc., McNeil-PPC, Inc., New River Pharmaceuticals, and Novartis Pharmaceuticals Corporation.
|
Commercial Support
This activity is supported by an educational grant from McNeil Pediatrics division of McNeil-PPC, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC
Disclaimers
The content of this video activity may include product information that is inconsistent with or outside of the approved labeling for these products in the United States. Before prescribing any medication, you must familiarize yourself with the manufacturer's product information.
To earn continuing education credit, view this online course and complete the posttest and evaluation provided. A passing score of 70% or more must be achieved on the posttest. A link is provided within this online activity to access the posttest and evaluation. You will have the option of printing a Statement of Credit for your records after submission of the evaluation.
CME LLC, McNeil Pediatrics and Ortho-McNeil Janssen Scientific Affairs, LLC are not responsible for the speaker's statements, materials, acts or omissions. |
|
Continuing Medical Education
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME credits from activities presented by ACCME accredited providers may be used toward American Osteopathic Association (AOA) Category 2-A requirements.
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
CME LLC is approved by the California Board of Registered Nursing, Provider No. CEP12748, and designates this educational activity for 1.0 contact hour for nurses.
The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ toward recertification requirements.
Content Originally Presented: October 11, 2007
Online Date: December 20, 2007
Credit Expiration Date: December 19, 2008
This activity is based on the symposium Improving Functional Outcomes in Adolescent and Adult ADHD: Efficacy and Safety of Pharmacologic Therapies at the 20th Annual U.S Psychiatric and Mental Health Congress in October, 2007 in Orlando, Fla. Participants who attended the live symposium mentioned above cannot claim credit for this activity.
|
